ArticleFrontiers in immunology2026
Firsekibart for steroid withdrawal in glucocorticoid-dependent refractory gout: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoid dependence presents a major therapeutic hurdle in refractory gout, often preventing successful steroid tapering and perpetuating a cycle of recurrent flares. We describe a 53-year-old male with severe tophaceous gout and glucocorticoid dependence, experiencing frequent flares upon reducing methylprednisolone below 16 mg/day despite urate-lowering therapy (ULT). After conventional anti-inflammatory agents proved inadequate, a single 200-mg subcutaneous dose of firsekibart (formerly known as genakumab), an anti-interleukin-1β (IL-1β) monoclonal antibody, was administered. Following this intervention, gout flares ceased immediately, enabling a glucocorticoid taper and eventual discontinuation over the following two months. Inflammatory markers normalized, renal function stabilized, and serum urate decreased. This case demonstrates the potential of firsekibart as a potent steroid-sparing agent, effectively breaking the cycle of glucocorticoid dependency in refractory gout and enabling successful long-term management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.